Articles tagged "Immunosuppression"

2018 American Transplant Congress
Single Center Experience of HLA-Related Donor Specific Antibody in Living Donor Liver Transplantation
H. Egawa,¹ Y. Kotera,¹ A. Ohmori,¹ S. Yamashita,¹ T. Kato,¹ S. Nemoto,¹ T. Ishizuka,² M. Yamamoto.¹
¹Surgery, Tokyo Women's Medical University, Tokyo, Japan; ²Clinical Laboratory, Tokyo Women's Medical University, Tokyo, Japan.
Although impact of donor specific antibody in liver transplantation has been recognized, significance of desensitization is not established yet. Our aim is to share our…
2018 American Transplant Congress
Multi-Targeting Desensitization Therapy Alters Peripheral B-Cell Homeostasis and Suppresses Recall Alloantibody Responses
I. Kim, G. Wu, N-.N. Chai, A. Klein, S. Jordan.
CTC/Surgery, Cedars-Sinai Medical Center, Los Angeles, CA.
Purpose: Occurring of donor specific antibodies (DSA) is injurious to organ transplant. Development of immunotherapies to suppress DSA, therefore, has been one of the strategic…
2018 American Transplant Congress
Designing Novel Selective Immunoproteasome Inhibitors Reveals a Critical Role of the Immunoproteasome in Protecting Antibody Secreting B Cells from Apoptosis
J. Assaker,¹ N. Murakami,¹ S. Eskandari,¹ M. Uehara,¹ C. Nathan,² H. Li,³ G. Lin,² J. Azzi.¹
¹Transplantation Renal Center, Harvard Medical School, Boston; ²Microbiology and Immunology, Weill Cornell Medicine, New York; ³Cryo-EM Structural Biology Laboratory, Van Andel Research Institute, Grand Rapids.
Constitutive proteasomes (c-20S) are ubiquitously-expressed cellular proteases that degrade polyubiquitinated proteins and regulate cell functions. Its inhibitor, bortezomib, is a plasma cell-targeted therapy used in…
2018 American Transplant Congress
Tissue Talks: Graft´s Histological Findings 10 Years after Belatacept or CNI
G. Mondragon-Ramirez,¹ N. Uribe-Uribe,² J. Arreola-Guerra,⁵ R. Reyes-Acevedo,⁵ M. Vilatoba,³ J. Furuzawa-Carballeda,⁴ A. Lopez-Toledo,¹ G. Mondragon-Salgado,¹ J. Alberu.³
¹Inst Mex de Trasplantes, Cuernavaca, Mexico; ²Pathology, Inst Nal de C. Médicas y Nutrición SZ, Mexico City, Mexico; ³Transplantation, Inst Nal de C. Médicas y Nutrición SZ, Mexico City, Mexico; ⁴Immunology, Inst Nal de C. Médicas y Nutrición SZ, Mexico City, Mexico; ⁵Transplantation, C Hospital Miguel Hidalgo, Aguascalientes, Mexico.
The BENEFIT study demonstrated that 7 yrs after kidney transplantation (KT), mean eGFR, patient and graft survival, were significantly higher in the belatacept group than…
2018 American Transplant Congress
Transplantation Tolerance Prevents CMV Reactivation and Preserves Kidney Allograft Function in a D+/R- Transplant Setting
A. Dangi,¹ J-.J. Wang,² M. Burnette,¹ Z. Zhang,² X. Luo.^1,2
¹Division of Nephrology and Hypertension, Department of Medicine, Northwestern University, Chicago, IL; ²Comprehensive Transplant Center, Department of Surgery, Northwestern University, Chicago, IL.
Background: Immune responses to cytomegalovirus (CMV) infection may precipitate acute/chronic graft rejection in immunocompromised transplant recipients. CMV infection can be primary or its reactivation from…
2018 American Transplant Congress
Patients Converted to Belatacept Show Different Immunophenotyping Compared with De Novo Belatacept-Treated Patients
M. Rial,¹ F. Caro,² A. Nella,² D. Guerrieri,² L. León,¹ P. Uva,¹ E. Chuluyan,² D. Casadei.¹
¹Instituto de Nefrología, Nephrology, Buenos Aires, Argentina; ²CEFYBO, UBA, CONICET, Buenos Aires, Argentina.
The incidence of adverse clinical events mainly in early, but not late post-transplantation such as an increased rate of acute rejection precludes the use of…
2018 American Transplant Congress
Effect of Everolimus on Body Composition; 1-Year after Kidney Transplantation
M. Yoshikawa,¹ T. Ishimura,² S. Nishi.¹
¹Division of Nephrology, Kobe University Graduate School of Medicine, Kobe, Japan; ²Division of Urology, Kobe University Graduate School of Medicine, Kobe, Japan.
【Background】Weight gain, and especially visceral fat gain early after kidney transplantation has a worse outcome for metabolic disorder, graft function, and cardiovascular disease. The mammalian…
2018 American Transplant Congress
Human CD8⁺CD28^– T Cells Driven In Vitro by IL-15 Suppress in Allo-Specific Manner Partially through PD-1:PD-L1 Pathway
F. Feng,^1,2 G. Liu,¹ P. Zhu,¹ M. Zhu,¹ X. Lu,¹ J. Liu,² X. Luo,³ Y. Liu,¹ Y. Yu.²
¹Department of Immunology, School of Basic Medical Science, Southern Medical University, Guangzhou, Guangdong, China; ²Department of Urology, Guangdong General Hospital, Guangdong Academy of Medical Sciences, Guangzhou, Guangdong, China; ³Department of Medicine, Northwestern University Feinberg School of Medicine, Chicago, IL.
Background: CD8+CD28- T suppressor cells (Ts) have emerged as an important modulator of alloimmunity, but the in vitro inducibility of Ts subsets is rather unclear.…
2018 American Transplant Congress
Once-Daily versus Twice-Daily Tacrolimus in De Novo Living Kidney Transplantation Patients: A Multicenter, Parallel Group, Open-Label, 5-Year Randomized Noninferiority Trial
Y. Kakuta,¹ M. Okumi,¹ K. Unagami,² M. Furusawa,¹ H. Ishida,¹ K. Tanabe.¹
¹Urology, Tokyo Women's Medical University, Tokyo, Japan; ²Nephrology, Tokyo Women's Medical University, Tokyo, Japan.
BackgroundTacrolimus is available as twice-daily (TAC-BID) and once-daily (TAC-QD) formulations. Findings from pharmacokinetic and short-term trials are available. However, results from long-term trials are limited.We…
2018 American Transplant Congress
Triptolide Reduces the Required Dose of Tacrolimus by Attenuating Inflammation, Enhancing Immunosuppression, and Increasing Donor Chimerism in a Heterotopic Hindlimb Transplantation Model
C. Gu, F. Liu, J. Yang.
Plastic and Reconstructive Surgery, Shanghai Ninth Hospital, Shanghai, China.
Background: Induction of tolerance and minimizing the toxicity of immuno- suppression are two fundamental goals in vascularized composite allotrans- plantation. Accumulating data indicate that triptolide…